Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–54
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years to 54 years with a diagnosis of AD according to the American Academy of Dermatology (AAD) Consensus Criteria (2014) present for at least 12 months
History of inadequate response to topical corticosteroids (TCS) of medium, high, or higher potency (with or without topical calcineurin inhibitors)
Subjects with previous systemic treatment for AD are also considered as inadequate responders to topical treatments and are potentially eligible to be included in the study after appropriate washout.
Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3
You may not be if
Treatment with a biologic product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
* Systemic corticosteroids
* Systemic immunosuppressants
* Phototherapy
* Janus kinase inhibitors
Treatment with any of the following medications or therapies within 1 week, prior to Day 1:
* TCS of any potency
* Topical calcineurin inhibitors (TCI)
* Topical Phosphodiesterase-4 inhibitors (PDE4)
* Other topical immunosuppressive agents
* Combination topical agents containing a corticosteroid or calcineurin inhibiting component, PDE4 inhibitors, or other topical immunosuppressive agents
Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 pre-randomization.
Treatment with any meningococcal vaccine within 1 year prior to screening, or treatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5 years prior to screening
